PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
Lucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwide Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submission PAVmed engaged with FDA on PortIO and Octeris Conference call and webcast...
Covered in this story
Call it yourself
No calls on $LUCD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lucid Diagnostics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.